Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

Gilead’s giving supports community-driven solutions to help end the HIV epidemic for everyone, everywhere, and tackle global ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...